July 2nd 2025
New advisory endorsed by major medical groups outlines state of health care around GLP-1 drugs and obesity treatment.
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
View More
Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
View More
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
View More
Medicare's Alzheimer's math is fuzzy -- but critics are missing the bigger picture
May 14th 2024The Biden administration recently warned that Medicare could spend $3.5 billion on a new category of Alzheimer's drugs in 2025 alone – a figure vastly higher than what experts in the field predict – leading many to question the math.